Orphazyme CEO excited for milestone: We are preparing for all scenarios
In Q3, when Orphazyme receives the first phase III results of the main asset arimoclomol, the company will reach a major milestone. This is according to CEO Anders Hinsby, who has confidence in the study but is preparing for all possible scenarios.
BY KEVIN GRØNNEMANN
Danish biotech company Orphazyme is about to be put to the biggest test. Between July and September this year, the company will have the results from the first phase III studies of its high hope arimoclomol.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Orphazyme obtains special status in the US
For abonnenter
Orphazyme CEO proud of "giant milestone"
For abonnenter
